Read More

Mirati Therapeutics And Aadi Bioscience Partner To Evaluate The Combination Of Adagrasib With Nab-sirolimus In Patients With Advanced Non-Small Cell Lung Cancer And Other Solid Tumors With A KRAS[G12C] Mutation

Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial stage biopharmaceutical company focused on developing and commercializing

AADI

Read More

Aadi Bioscience: Q1 Earnings Insights

Aadi Bioscience (NASDAQ:AADI) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Aadi Bioscience beat estimated earnings by 7.04%, reporting an EPS of $-0.66 versus an estimate of $-0.71.

AADI